ORAMED PHARMACEUTICALS INC (ORMP) Stock Price, Forecast & Analysis
USA - NASDAQ:ORMP - US68403P2039 - Common Stock
ORMP Key Statistics, Chart & Performance
The current stock price of ORMP is 2.33 USD. In the past month the price increased by 2.18%.
ORMP Latest News, Press Relases and Analysis
ORMP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 46.68 | 971.59B | ||
| JNJ | JOHNSON & JOHNSON | 19.22 | 480.37B | ||
| MRK | MERCK & CO. INC. | 10.99 | 241.91B | ||
| PFE | PFIZER INC | 7.87 | 143.19B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.22 | 96.38B | ||
| ZTS | ZOETIS INC | 18.61 | 52.29B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.56 | 22.92B | ||
| VTRS | VIATRIS INC | 4.57 | 12.42B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.95 | 10.47B | ||
| CORT | CORCEPT THERAPEUTICS INC | 84.77 | 7.86B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.26B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 4.07B |
Related stock screener links
About ORMP
Company Profile
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
Company Info
ORAMED PHARMACEUTICALS INC
1185 Avenue Of The Americas, 3Rd Floor
New York City NEW YORK 10036 US
CEO: Nadav Kidron
Employees: 13
Phone: 16468441164
ORAMED PHARMACEUTICALS INC / ORMP FAQ
What does ORMP do?
Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. The company is headquartered in New York City, New York and currently employs 13 full-time employees. The company went IPO on 2002-04-01. The firm has developed an oral dosage form intended to withstand the harsh environment of the stomach and effectively deliver active biological insulin or other proteins. Its Protein Oral Delivery (POD) technology is designed to protect drug integrity and increase absorption. Its pipeline includes ORMD-0801 (Oral Insulin) Diabetes, ORMD-0801 (Oral Insulin) NASH, and ORMD 0901 (Oral GLP-1). Its oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes through oral delivery of insulin at an earlier stage of treatment. Its oral insulin capsule (ORMD-0801) has shown a reduction of liver fat content in early clinical trials. The company is also developing an oral Glucagon-like peptide-1 (GLP-1) analog capsule (ORMD-0901), which is an incretin hormone that stimulates the secretion of insulin from the pancreas.
What is the stock price of ORAMED PHARMACEUTICALS INC today?
The current stock price of ORMP is 2.33 USD. The price decreased by -0.43% in the last trading session.
Does ORAMED PHARMACEUTICALS INC pay dividends?
ORMP does not pay a dividend.
What is the ChartMill rating of ORAMED PHARMACEUTICALS INC stock?
ORMP has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the employee count for ORMP stock?
ORAMED PHARMACEUTICALS INC (ORMP) currently has 13 employees.
Can you provide the upcoming earnings date for ORAMED PHARMACEUTICALS INC?
ORAMED PHARMACEUTICALS INC (ORMP) will report earnings on 2026-03-25, after the market close.
ORMP Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ORMP. When comparing the yearly performance of all stocks, ORMP turns out to be only a medium performer in the overall market: it outperformed 66.56% of all stocks.
ORMP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORMP. No worries on liquidiy or solvency for ORMP as it has an excellent financial health rating, but there are worries on the profitability.
ORMP Financial Highlights
Over the last trailing twelve months ORMP reported a non-GAAP Earnings per Share(EPS) of -0.18. The EPS decreased by -228.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -14.94% | ||
| ROE | -15.64% | ||
| Debt/Equity | 0 |
ORMP Forecast & Estimates
6 analysts have analysed ORMP and the average price target is 3.32 USD. This implies a price increase of 42.27% is expected in the next year compared to the current price of 2.33.